Evidence map›Paper›PMID 32193215›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2020

Species Differences of Bile Acid Redox Metabolism: Tertiary Oxidation of Deoxycholate is Conserved in Preclinical Animals.

Qiuhong Lin, Xianwen Tan, Wenxia Wang, Wushuang Zeng, Lanlan Gui, Mingming Su, Changxiao Liu, Wei Jia, Liang Xu, Ke Lan

Open access · bronzeAbstract read
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Secondary bile acids are associated with body lipid accumulation in obese pigs.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Qiuhong LinKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, HI, (M.S., W.J.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., K.L.).
Xianwen TanKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, HI, (M.S., W.J.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., K.L.).
Wenxia WangKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, HI, (M.S., W.J.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., K.L.).
Wushuang ZengKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, HI, (M.S., W.J.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., K.L.).
Lanlan GuiKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, HI, (M.S., W.J.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., K.L.).
Mingming SuKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, HI, (M.S., W.J.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., K.L.).
Changxiao LiuKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, HI, (M.S., W.J.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., K.L.).
Wei JiaKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, HI, (M.S., W.J.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., K.L.).
Liang XuKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, HI, (M.S., W.J.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., K.L.).
Ke LanKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, HI, (M.S., W.J.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (Q.L., X.T., W.W., W.Z., L.G., K.L.) lanwoco@scu.edu.cn.ORCID 0000-0002-9237-9219
University of Hawaiʻi at Mānoa · US

Funding

University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2M
NCI NIH HHS P30 CA071789
6 · The paper itself

Abstract

It was recently disclosed that CYP3A is responsible for the tertiary stereoselective oxidations of deoxycholic acid (DCA), which becomes a continuum mechanism of the host-gut microbial cometabolism of bile acids (BAs) in humans. This work aims to investigate the species differences of BA redox metabolism and clarify whether the tertiary metabolism of DCA is a conserved pathway in preclinical animals. With quantitative determination of the total unconjugated BAs in urine and fecal samples of humans, dogs, rats, and mice, it was confirmed that the tertiary oxidized metabolites of DCA were found in all tested animals, whereas DCA and its oxidized metabolites disappeared in germ-free mice. The in vitro metabolism data of DCA and the other unconjugated BAs in liver microsomes of humans, monkeys, dogs, rats, and mice showed consistencies with the BA-profiling data, confirming that the tertiary oxidation of DCA is a conserved pathway. In liver microsomes of all tested animals, however, the oxidation activities toward DCA were far below the murine-specific 6

Indexed as

AnimalsBile Acids and SaltsCytochrome P-450 CYP3ADogsDrug Evaluation, PreclinicalFecesFemaleGerm-Free LifeHumansHydroxylationMaleMiceMicrosomes, LiverOxidation-ReductionRatsSpecies SpecificityBile Acids and SaltsCytochrome P-450 CYP3A

Identifiers

PMID32193215
PMCPMC11022903
OpenAlexW3011147288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.